RXRX
RECURSION PHARMACEUTICALS, INC.
Latest Form 4:Sale$100KbyBorgeson Blake (Director) · filed Sep 2, 2026
RECURSION PHARMACEUTICALS, INC. (RXRX) has 71 SEC Form 4 filings (109 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Sep 2, 2026.
Inside the rolling window, 5 insiders at RECURSION PHARMACEUTICALS, INC. reported no open-market purchases and 36 open-market sales totaling $9.3M. The most active filer is Director Gibson Christopher with 18 filings. Insiders have net sold $1.7M over the trailing 6 months. The most recent open-market filing is a sale of 30,000 shares by Director Borgeson Blake, dated Sep 1, 2026, worth $100K.
- Industry:Biotechnology
- CEO:Najat Khan
- Employees:600
- HQ:Salt Lake City, UT, US
- IPO:2021-04-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$9.3M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$1.8B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 30,000 | $100K | Sep 2 | SEC ↗ | |
| Director | Sale | 30,000 | $98K | Aug 6 | SEC ↗ | |
| Director | Sale | 40,000 | $159K | Jul 9 | SEC ↗ | |
| Director | Sale | 3,963 | $13K | Jun 22 | SEC ↗ | |
| Director | Sale | 40,000 | $145K | Jun 5 | SEC ↗ | |
| CEO and President | Sale | 23,588 | $84K | Jun 5 | SEC ↗ | |
| Director | Sale | 30,000 | $110K | Jun 4 | SEC ↗ | |
Bumpus NamandjeFirst filing | Director | Sale | 4,386 | $16K | Jun 4 | SEC ↗ |
| Director | Sale | 40,000 | $123K | May 27 | SEC ↗ | |
| Director | Sale | 40,000 | $135K | May 8 | SEC ↗ | |
| Director | Sale | 30,000 | $106K | May 7 | SEC ↗ | |
| Director | Sale | 40,000 | $144K | Apr 24 | SEC ↗ | |
| Director | Sale | 40,000 | $124K | Apr 8 | SEC ↗ | |
| Director | Sale | 30,000 | $93K | Apr 8 | SEC ↗ | |
| Director | Sale | 40,000 | $130K | Mar 25 | SEC ↗ | |
| Chief Financial Officer | Sale | 7,956 | $27K | Mar 18 | SEC ↗ | |
| CEO and President | Sale | 28,298 | $95K | Mar 11 | SEC ↗ | |
| Director | Sale | 170,000 | $588K | Mar 4 | SEC ↗ | |
| Director | Sale | 40,000 | $138K | Feb 19 | SEC ↗ | |
| Chief Financial Officer | Sale | 13,426 | $41K | Feb 19 | SEC ↗ | |
| Director | Sale | 40,000 | $165K | Feb 6 | SEC ↗ | |
| Director | Sale | 220,000 | $924K | Feb 6 | SEC ↗ | |
| Director | Sale | 40,000 | $179K | Jan 22 | SEC ↗ | |
| Director | Sale | 220,000 | $959K | Jan 8 | SEC ↗ | |
| Director | Sale | 40,000 | $170K | Jan 7 | SEC ↗ | |
Taylor Ben RFirst filing | Chief Financial Officer | Sale | 21,383 | $89K | Dec 30 | SEC ↗ |
Khan NajatFirst filing | Chief R&D Commercial Officer | Sale | 124,403 | $549K | Dec 29 | SEC ↗ |
| Chief Executive Officer | Sale | 40,000 | $180K | Dec 19 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $185K | Dec 5 | SEC ↗ | |
Borgeson BlakeFirst filing | Director | Sale | 220,000 | $961K | Dec 4 | SEC ↗ |
| Chief Executive Officer | Sale | 40,000 | $166K | Nov 19 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $208K | Nov 6 | SEC ↗ | |
| Chief Executive Officer | Sale | 100,000 | $570K | Oct 24 | SEC ↗ | |
| Chief Executive Officer | Sale | 100,000 | $604K | Oct 10 | SEC ↗ | |
| Chief Executive Officer | Sale | 100,000 | $476K | Sep 26 | SEC ↗ | |
Gibson ChristopherFirst filing | Chief Executive Officer | Sale | 100,000 | $471K | Sep 12 | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does RXRX have?
RECURSION PHARMACEUTICALS, INC. (RXRX) has 71 SEC Form 4 filings (109 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Sep 2, 2026.
When was the most recent SEC Form 4 filing for RXRX?
The most recent Form 4 filing for RXRX on Tracefour is dated Sep 2, 2026.
Who is the most active insider at RXRX?
The most active SEC Form 4 filer at RXRX in the rolling window is Director Gibson Christopher, with 18 filings.
What is the net insider flow at RXRX over the last 6 months?
Over the trailing 180 days, insiders at RXRX have net sold $1.7M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at RXRX in the current window?
Inside the rolling window, insiders at RXRX bought $0 and sold $9.3M based on SEC Form 4 filings.
Can I get alerts for RXRX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at RECURSION PHARMACEUTICALS, INC. (RXRX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
RECURSION PHARMACEUTICALS, INC. is in the Healthcare sector.